Home › Research › Risk genes beyond APOE
Pharmacological Advances in Targeting Neuroinflammation for Alzheimer’s Disease
Kunal .. Journal of Pharmaceutical Technology Research and Management, 2026-01-09
Topic: Amyloid, tau and blood-test diagnosis
Mechanistic studies demonstrate that pharmacological modulation of microglial phenotypes inhibition of pro inflammatory mediators TNF alpha IL 1 IL 6 and targeting pathways such as NF kappa B NLRP3 inflammasome p38 MAPK JAK STAT and TREM2 can attenuate neuroinflammatory cascades and reduce amyloid beta and tau associated neurotoxicity. However clinical translation remains inconsistent due to limited blood brain barrier permeability off target toxicity and patient heterogeneity. Advanced nanocarrier based delivery systems and intranasal strategies show promise in improving brain bioavailability and therapeutic precision. Targeting neuroinflammation represents a mechanistically robust avenue for disease modification in AD. Future therapeutic success will likely depend on integrated multimodal strategies combining precise inflammatory pathway modulation with advanced brain targeted drug delivery and biomarker guided patient stratification.
Key findings
- Mechanistic studies demonstrate that pharmacological modulation of microglial phenotypes inhibition of pro inflammatory mediators TNF alpha IL 1 IL 6 and targeting pathways such as NF kappa B NLRP3 inflammasome p38 MAPK JAK STAT and TREM2 can attenuate neuroinflammatory cascades and reduce amyloid beta and tau associated neurotoxicity.
- However clinical translation remains inconsistent due to limited blood brain barrier permeability off target toxicity and patient heterogeneity.
- Advanced nanocarrier based delivery systems and intranasal strategies show promise in improving brain bioavailability and therapeutic precision.
- Targeting neuroinflammation represents a mechanistically robust avenue for disease modification in AD.
- Future therapeutic success will likely depend on integrated multimodal strategies combining precise inflammatory pathway modulation with advanced brain targeted drug delivery and biomarker guided patient stratification.
Why it matters
This review reports that modulating neuroinflammation reduced amyloid and tau related toxicity in mechanistic studies, but clinical translation remains inconsistent due to problems such as limited brain penetration and patient heterogeneity. It does not show that any neuroinflammation-targeting treatment cures or prevents Alzheimer's disease.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 28/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 26 of the 93 points we could judge it on, which is 28 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Pharmaceutical Technology Research and Management) |
| Journal's citation record | 0 / 4 | Journal of Pharmaceutical Technology Research and Management: journal h-index 11 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Kunal . holds only 2 work(s), too few to judge a track record — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 26 of the 93 points we could judge it on is 28 out of 100. |
| Total | 28 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.15415/jptrm.2025.131010
- Original source →
- Free full text: Journal of Pharmaceutical Technology Research and Management →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Kunal. (2026). Pharmacological Advances in Targeting Neuroinflammation for Alzheimer’s Disease. Journal of Pharmaceutical Technology Research and Management. https://doi.org/10.15415/jptrm.2025.131010
Vancouver
Kunal. Pharmacological Advances in Targeting Neuroinflammation for Alzheimer’s Disease. Journal of Pharmaceutical Technology Research and Management. 2026. doi:10.15415/jptrm.2025.131010.
BibTeX
@article{kunal2026-bde583e5,
author = {Kunal},
title = {{Pharmacological Advances in Targeting Neuroinflammation for Alzheimer’s Disease}},
journal = {Journal of Pharmaceutical Technology Research and Management},
year = {2026},
doi = {10.15415/jptrm.2025.131010},
url = {https://doi.org/10.15415/jptrm.2025.131010}
}